Lakefront Biotherapeutics American Depositary Shares
LKFT
84 hedge funds and large institutions have $551M invested in Lakefront Biotherapeutics American Depositary Shares in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 21 closing their positions.
2% more funds holding
Funds holding: 82 → 84 (+2)
10% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 21
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
0.02% more ownership
Funds ownership: 19.64% → 19.66% (+0.02%)
23% less capital invested
Capital invested by funds: $720M → $551M (-$169M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
54% less call options, than puts
Call options by funds: $6.6M | Put options by funds: $14.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.73M |
| 3 |
Millennium Management
New York
|
+$6.97M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.62M |
| 5 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$6.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$16.9M |
| 2 |
JP Morgan Chase
New York
|
-$15M |
| 3 |
Optiver Holding
Amsterdam,
Netherlands
|
-$10.6M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.33M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.83M |
LKFT Hedge Fund Activity: Q3 2022 in Review
84 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q3 2022, worth a combined $551M — down 23% from $720M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new LKFT positions and 21 closed out — a net gain of 2 holders — while 24 added to existing stakes and 23 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $22.1M. The largest seller was Jennison Associates, exiting entirely with an estimated $16.9M sold.
- 84 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q3 2022, up from 82 in Q2 2022.
- Funds reported $551M of Lakefront Biotherapeutics American Depositary Shares stock for Q3 2022, down 23% quarter-over-quarter.
- 23 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q3 2022 and 21 closed out, a net change of +2 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q3 2022 was Wellington Management Group, an estimated $22.1M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q3 2022 was Jennison Associates, an estimated $16.9M sold.
Based on aggregated 13F filings for Q3 2022.